Neuropathic pain is a major symptom of Fabry-Anderson disease (FD). It develops in childhood, is life-lasting, and resists current therapies; finding new therapeutic strategies is urgently needed. We demonstrate that neuroinflammation control effectively relieves FD pain. We used 2 pharmacological approaches: the microglial inhibitor minocycline and the block of the activity of the chemokine prokineticin-2 with the specific receptor antagonist PC1 (patented compound 1). Ten- and 25-week-old male GLA-/- mice (the FD murine model) were used. These mice were characterized by mechanical allodynia, thermal hyperalgesia, hyposensitivity to cold stimuli, and abdominal pain. Two weeks of treatment with minocycline or PC1 successfully counteracted sensory alterations. A significant inflammatory state, characterized by high levels of prokineticin-2 and proinflammatory cytokines, was present in the FD gut. The sciatic nerve showed initial severe neuroinflammation that attenuated over time. In dorsal root ganglia, neuroinflammation was severe and persistent with prokineticin-2, proinflammatory cytokines, ionized calcium-binding adapter molecule 1, and glial fibrillary acidic protein overexpression; histone demethylases KDM6A and B were also upregulated. We highlighted neuroinflammation in the spinal cord that increased over time. Treatment with minocycline or PC1 significantly counteracted inflammation and neuroinflammation, reducing prokineticin-2 and proinflammatory cytokines levels and increasing anti-inflammatory factor PPARγ expression. Both treatments prevented the onset of micro- and astrogliosis in the spinal cord. We underline the role of neuroinflammation and microglia in FD pain and suggest that treatments that control the activity of the prokineticin system, glial activation, and the production of proinflammatory cytokines and increase anti-inflammatory mediators have a therapeutic effect on pain in FD.

The prokineticin system and glia cells as pharmacological targets to control neuroinflammation and to relieve pain in a murine model of Fabry–Anderson disease / G. Galimberti, S. Franchi, G. Amodeo, P. Romualdi, S. Candeletti, L. Rullo, L. Losapio, V. Onnis, D. Moi, B. Riboldi, G. Magni, S. Ceruti, P. Sacerdote. - In: PAIN. - ISSN 1872-6623. - (2025 Sep 25). [Epub ahead of print] [10.1097/j.pain.0000000000003818]

The prokineticin system and glia cells as pharmacological targets to control neuroinflammation and to relieve pain in a murine model of Fabry–Anderson disease

G. Galimberti
Primo
;
S. Franchi
Secondo
;
G. Amodeo;B. Riboldi;G. Magni;S. Ceruti
Penultimo
;
P. Sacerdote
Ultimo
2025

Abstract

Neuropathic pain is a major symptom of Fabry-Anderson disease (FD). It develops in childhood, is life-lasting, and resists current therapies; finding new therapeutic strategies is urgently needed. We demonstrate that neuroinflammation control effectively relieves FD pain. We used 2 pharmacological approaches: the microglial inhibitor minocycline and the block of the activity of the chemokine prokineticin-2 with the specific receptor antagonist PC1 (patented compound 1). Ten- and 25-week-old male GLA-/- mice (the FD murine model) were used. These mice were characterized by mechanical allodynia, thermal hyperalgesia, hyposensitivity to cold stimuli, and abdominal pain. Two weeks of treatment with minocycline or PC1 successfully counteracted sensory alterations. A significant inflammatory state, characterized by high levels of prokineticin-2 and proinflammatory cytokines, was present in the FD gut. The sciatic nerve showed initial severe neuroinflammation that attenuated over time. In dorsal root ganglia, neuroinflammation was severe and persistent with prokineticin-2, proinflammatory cytokines, ionized calcium-binding adapter molecule 1, and glial fibrillary acidic protein overexpression; histone demethylases KDM6A and B were also upregulated. We highlighted neuroinflammation in the spinal cord that increased over time. Treatment with minocycline or PC1 significantly counteracted inflammation and neuroinflammation, reducing prokineticin-2 and proinflammatory cytokines levels and increasing anti-inflammatory factor PPARγ expression. Both treatments prevented the onset of micro- and astrogliosis in the spinal cord. We underline the role of neuroinflammation and microglia in FD pain and suggest that treatments that control the activity of the prokineticin system, glial activation, and the production of proinflammatory cytokines and increase anti-inflammatory mediators have a therapeutic effect on pain in FD.
No
English
Neuroinflammation; Pain; Prokineticin system; Glial cells; Minocycline; Fabry disease; GLA-/- mice
Settore BIOS-11/A - Farmacologia
Articolo
Esperti anonimi
Pubblicazione scientifica
   Pharmacological block of the prokineticin system and of microglia activation to treat pain and mood disorders in Fabry-Anderson disease
   FONDAZIONE TELETHON ETS
25-set-2025
25-set-2025
Wolters Kluwer
Epub ahead of print
Periodico con rilevanza internazionale
manual
Aderisco
info:eu-repo/semantics/article
The prokineticin system and glia cells as pharmacological targets to control neuroinflammation and to relieve pain in a murine model of Fabry–Anderson disease / G. Galimberti, S. Franchi, G. Amodeo, P. Romualdi, S. Candeletti, L. Rullo, L. Losapio, V. Onnis, D. Moi, B. Riboldi, G. Magni, S. Ceruti, P. Sacerdote. - In: PAIN. - ISSN 1872-6623. - (2025 Sep 25). [Epub ahead of print] [10.1097/j.pain.0000000000003818]
open
Prodotti della ricerca::01 - Articolo su periodico
13
262
Article (author)
Periodico con Impact Factor
G. Galimberti, S. Franchi, G. Amodeo, P. Romualdi, S. Candeletti, L. Rullo, L. Losapio, V. Onnis, D. Moi, B. Riboldi, G. Magni, S. Ceruti, P. Sacerdot...espandi
File in questo prodotto:
File Dimensione Formato  
Pain_Fabry_2025.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Licenza: Creative commons
Dimensione 4.97 MB
Formato Adobe PDF
4.97 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1186415
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
  • OpenAlex ND
social impact